Literature DB >> 13268474

Progress report on mestinon bromide (pyridostigmine bromide).

K E OSSERMAN.   

Abstract

Entities:  

Keywords:  MYASTHENIA GRAVIS/therapy; PARASYMPATHOMIMETICS/therapeutic use

Mesh：

Substances：

Year:  1955        PMID： 13268474     DOI： 10.1016/s0002-9343(55)80018-6

Source DB:  PubMed          Journal:  Am J Med        ISSN： 0002-9343            Impact factor:   4.965


× No keyword cloud information.
  10 in total

1.  [Physiological and pharmacological significance of cholinesterase and anticholinesterase].

Authors:  G B KOELLE
Journal:  Klin Wochenschr       Date:  1958-11-15

2.  [Not Available].

Authors:  K E OSSERMAN
Journal:  Klin Wochenschr       Date:  1959-01-01

3.  MYASTHENIA gravis.

Authors: 
Journal:  Br Med J       Date:  1956-06-02

4.  [Clinical studies on the deblocking properties of prostigmine in ganglion blockade induced by ecolid and pendiomide].

Authors:  J GOERRE
Journal:  Klin Wochenschr       Date:  1957-11-15

Review 5.  Diagnosis and management of autoimmune myasthenia gravis.

Authors:  Corrado Angelini
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

6.  Glycopyrrolate and cardiac dysrhythmias in geriatric patients after reversal of neuromuscular blockade.

Authors:  S Muravchick; W D Owens; J A Felts
Journal:  Can Anaesth Soc J       Date:  1979-01

7.  Myasthenial gravis; problems in diagnosis.

Authors:  C HERRMANN; A S ROSE
Journal:  Calif Med       Date:  1957-12

8.  Current and emerging therapies for the treatment of myasthenia gravis.

Authors:  Renato Mantegazza; Silvia Bonanno; Giorgia Camera; Carlo Antozzi
Journal:  Neuropsychiatr Dis Treat       Date:  2011-03-22       Impact factor: 2.570

9.  Add-on Pyridostigmine Enhances CD4+ T-Cell Recovery in HIV-1-Infected Immunological Non-Responders: A Proof-of-Concept Study.

Authors:  Sergio I Valdés-Ferrer; José C Crispín; Pablo F Belaunzarán-Zamudio; Carlos A Rodríguez-Osorio; Bernardo Cacho-Díaz; Jorge Alcocer-Varela; Carlos Cantú-Brito; Juan Sierra-Madero
Journal:  Front Immunol       Date:  2017-10-18       Impact factor: 7.561

Review 10.  Current Treatment of Myasthenia Gravis.

Authors:  Mohammed K Alhaidar; Sumayyah Abumurad; Betty Soliven; Kourosh Rezania
Journal:  J Clin Med       Date:  2022-03-14       Impact factor: 4.241
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.